恒瑞医药：收到HRS-1167片临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of HRS-1167, a second-generation PARP inhibitor developed in-house, indicating potential for both monotherapy and combination therapy in treating more patients [1] Company Summary - Heng Rui Medicine (600276.SH) announced the receipt of the clinical trial approval notice for HRS-1167 from the National Medical Products Administration [1] - HRS-1167 is a PARP1 small molecule inhibitor with higher selectivity and stronger affinity compared to first-generation PARP inhibitors [1] - The drug is currently in the early stages of clinical development and has the potential to treat a broader patient population as both a standalone and combination therapy [1] Industry Summary - The approval of HRS-1167 marks a significant step in the development of second-generation PARP inhibitors within the pharmaceutical industry [1] - The drug must undergo clinical trials and receive further review and approval from the National Medical Products Administration before it can be manufactured and marketed [1]